NCT07412288

First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants

A Phase 1, Randomized, Placebo-Controlled, First-in-Human, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered KT-579 in Healthy Adult Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Kymera Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a first-in-human study to evaluate safety and tolerability, pharmacokinetics, and pharmacodynamics of single and multiple dose levels of KT-579 in healthy male and female adult participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	KT-579	Oral drug
DRUG	Placebo	Oral drug

Timeline

• Start date: 2026-02-23
• Primary completion: 2026-12-01
• Completion: 2026-12-01
• First posted: 2026-02-17
• Last updated: 2026-02-27

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study